Here, we extended these findings and studied the effects of CDK6 degrader efficacy in two CDK6-dependent AML subtypes harbouring either KMT2A-MLLT3 or RUNX1-RUNX1T1. Here, MLLT3 is linked to acute myeloid leukemia.